Comparative Pharmacology
Head-to-head clinical analysis: HY PAM 25 versus REGROTON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HY PAM 25 versus REGROTON.
HY-PAM "25" vs REGROTON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxyzine pamoate is a piperazine antihistamine that acts as a histamine H1-receptor antagonist, thereby suppressing histamine-mediated responses in the skin and mucous membranes. Additionally, it exhibits anxiolytic and sedative properties through central nervous system depression via inhibition of subcortical regions.
Regroton is a combination of reserpine and chlorthalidone. Reserpine depletes catecholamines from peripheral sympathetic nerve endings by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to vasodilation and reduced heart rate. Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
25 mg orally once daily, preferably at bedtime, for short-term treatment of insomnia.
1 tablet (25 mg chlorthalidone / 50 mg metoprolol) orally once daily.
None Documented
None Documented
Terminal elimination half-life 6-8 hours in healthy adults; prolonged to 12-18 hours in renal impairment (CrCl <30 mL/min) and in elderly patients.
Terminal elimination half-life: 9-11 hours (mean 10 hours); clinical context: supports once-daily dosing in hypertension, steady-state reached in 3-4 days
Primarily renal (60-70% unchanged drug), with 30-40% biliary/fecal elimination as metabolites.
Renal: 70-80% (50% as unchanged drug, 20-30% as metabolites); Fecal: <5%
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination